BCRX
BioCryst Pharmaceuticals, Inc.
BCRX lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BCRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Strong | |
| Strong |
BCRX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BCRX PE Valuation
BCRX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BCRX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.66 | — |
| Q3 2026 | -$1.41 | -$1.36 |
| Q2 2026 | -$1.49 | -$1.31 |
| Q1 2026 | -$1.77 | -$1.51 |
| Q4 2025 | $1.21 | +$1.64 |
| Q3 2025 | -$0.05 | +$0.56 |
| Q2 2025 | -$0.18 | +$0.55 |
| Q1 2025 | -$0.26 | +$0.81 |
| Q4 2024 | -$0.43 | +$0.75 |
BCRX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $180.3M | +13% |
| Q2 2026 | $218.3M | +34% |
| Q1 2026 | $156.4M | +7.5% |
| Q4 2025 | $406.6M | +209% |
| Q3 2025 | $159.4M | +36% |
| Q2 2025 | $163.4M | +49% |
| Q1 2025 | $145.5M | +57% |
| Q4 2024 | $131.5M | +41% |
BCRX's revenue has grown year over year for 23 quarters in a row: $180M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +11 points |
| Q2 2026 | 45% | +27 points |
| Q1 2026 | -449% | -463 points |
| Q4 2025 | 64% | +68 points |
| Q3 2025 | 19% | +12 points |
| Q2 2025 | 18% | +10 points |
| Q1 2025 | 15% | +30 points |
| Q4 2024 | -3.4% | +42 points |
BCRX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BCRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.8M | -19% |
| Q2 2026 | $104.1M | +153% |
| Q1 2026 | -$62.2M | -$34.5M |
| Q4 2025 | $291.2M | +$297M |
| Q3 2025 | $40.3M | +392% |
| Q2 2025 | $41.1M | +$42.6M |
| Q1 2025 | -$27.7M | +$26.3M |
| Q4 2024 | -$5.9M | +$3.6M |
BCRX has burned cash in most quarters: $366M over the past year, about eight times what it generated the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BCRX on cash flow, with more consistent year-over-year improvement.
BCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.5M shares |
| 1 year | +22% | +47.7M shares |
| 3 years | +41% | +78M shares |
| 5 years | +51% | +90.3M shares |
| Available history | +74% | +113M shares |
BCRX has 268M diluted shares, up 22% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BCRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 6.1x | High |
BCRX has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over BCRX on leverage, with a lower net debt burden relative to earnings.
BCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 16.2 | Oversold |
BCRX's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BCRX PE vs Healthcare Sector
BCRX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.07 | 4.8% below |
| 20 week MA | $8.89 | 14% below |
| 50 week MA | $8.50 | 9.6% below |
| 100 week MA | $8.38 | 8.4% below |
| 200 week MA | $7.71 | 0.4% below |
BCRX is in a downtrend: it's below all five of its weekly moving averages, and 0.4% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.12 | $7.28 | +133% |
| 2021 | $7.28 | $13.9 | +91% |
| 2022 | $13.9 | $11.5 | -18% |
| 2023 | $11.5 | $5.99 | -48% |
| 2024 | $5.99 | $7.71 | +29% |
| 2025 | $7.71 | $7.63 | -1% |
| 2026 YTD | $7.63 | $7.68 | +0.7% |
BCRX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.